Sol-Gel Technologies Ltd. (SLGL)

Market Cap	175.48M
Revenue (ttm)	18.97M
Net Income (ttm)	-8.99M
Shares Out	2.79M
EPS (ttm)	-3.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	23,562
Open	58.00
Previous Close	58.00
Day's Range	58.00 - 66.20
52-Week Range	4.02 - 66.20
Beta	1.36
Analysts	Strong Buy
Price Target	50.00 (-20.62%)
Earnings Date	Nov 20, 2025

About SLGL

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has com...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 23, 2018
• Employees: 34
• Stock Exchange: NASDAQ
• Ticker Symbol: SLGL
• Website: https://www.sol-gel.com

Financial Performance

In 2024, Sol-Gel Technologies's revenue was $11.54 million, an increase of 642.47% compared to the previous year's $1.55 million. Losses were -$10.58 million, -61.16% less than in 2023.

Analyst Summary

According to one analyst, the rating for SLGL stock is "Strong Buy" and the 12-month stock price target is $50.0.

Price Target

$50.0

(-20.62% downside)

Analyst Consensus: Strong Buy